Kym­ri­ah wins sec­ond FDA OK, boost­ing hope for No­var­tis' low CAR-T sales

Af­ter dis­ap­point­ing in­vestors this year with slug­gish sales, the prospects for No­var­tis’ CAR-T ther­a­py Kym­ri­ah may be im­prov­ing. The FDA has hand­ed the phar­ma gi­ant its sec­ond ap­proval for the drug, the com­pa­ny said Tues­day af­ter­noon.

The drug, which was first ap­proved last Au­gust for pa­tients un­der 25 with B-cell pre­cur­sor acute lym­phoblas­tic leukemia, is now OK’ed to treat large B-cell lym­phoma. The can­cer must be re­lapsed or re­frac­to­ry, and the pa­tient must have gone through two or more lines of sys­temic ther­a­py first.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Associate

Alexandria Real Estate Equities

Cambridge, MA, USA